-+ 0.00%
-+ 0.00%
-+ 0.00%

Wells Fargo Maintains Equal-Weight on Bicara Therapeutics, Raises Price Target to $23

Benzinga·08/12/2026 12:22:51
Listen to the news
Wells Fargo analyst Eva Fortea Verdejo maintains Bicara Therapeutics (NASDAQ:BCAX) with a Equal-Weight and raises the price target from $16 to $23.